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I. PROJECT ID NUMBER, PUBLICATION  MORATORIUM INFORMATION, 
PROJECT DESCRIPTION: 
 
This manuscript is part of a pilot effort on the part of NIH staff and the Nature publishing group 
to provide a more convenient archive for "marker papers" to be published.  These "marker 
papers" are designed to provide the users of community resource data sets with information 
regarding the status and scope of individual community resource projects.  For further 
information see editorial in September 2010 edition of Nature Genetics (Nature Genetics, 42, 
729 (2010)), and the Nature Precedings HMP summary page. 
 
Project ID: 46331 
 
The vaginal microbiota play an important protective role in maintaining the health of women. 
Disruption of the mutualistic relationship that exists between bacterial communities in the vagina 
and their hosts can lead to bacterial vaginosis (BV), a condition in which lactic acid producing 
bacteria are supplanted by a diverse array of strictly anaerobic bacteria. BV has been shown to be 
an independent risk factor for adverse outcomes including preterm delivery and low infant birth 
weight, acquisition of sexually transmitted infections and HIV, and development of pelvic 
inflammatory disease. National surveys indicate the prevalence of BV among U.S. women is 
29.2%, and yet, despite considerable effort, the etiology of BV remains unknown. Moreover, 
there are no broadly effective therapies for the treatment of BV, and reoccurrence is common. In 
the proposed research we will test the overarching hypothesis that vaginal microbial 
community dynamics and activities are indicators of risk to BV. To do this, we propose to 
conduct a high resolution prospective study in which samples collected daily from 200 
reproductive-age women over two menstrual cycles are used to capture molecular events that 
take place before, during, and after the spontaneous remission of BV episodes. We will use 
modern genomic technologies to obtain the data needed to correlate shifts in vaginal microbial 
community composition and function, metabolomes, and epidemiological and behavioral 
metadata with the occurrence of BV to better define the syndrome itself and identify patterns that 
are predictive of BV. The three specific aims of the research are: (1) Evaluate the association 
between the dynamics of vaginal microbial communities and risk to BV by characterizing the 
community composition of vaginal specimens archived from a vaginal douching cessation study 
in which 33 women self-collected vaginal swabs twice-weekly for 16 weeks; (2) Enroll 135 
women in a prospective study in which self-collected vaginal swab samples and secretions are 
collected daily along with data on the occurrence of BV, vaginal pH, and information on time 
varying habits and practices; (3) Apply model-based statistical clustering and classification 
approaches to associate the microbial community composition and function, with metadata and 
clinical diagnoses of BV. The large body of information generated will facilitate understanding 
vaginal microbial community dynamics, the etiology of BV, and drive the development of better 
diagnostic tools for BV. Furthermore, the information will enable a more personalized and 
effective treatment of BV and ultimately help prevent adverse sequelae associated with this 
highly prevalent disruption of the vaginal microbiome.   
 
 
 
II. DATA QUALITY:  
 
Sequencing quality control: Through the use of automated reports, the LIMS at the Genomic 
Resource Center (GRC) at the Institute for Genome Sciences enables staff to monitor data 
quality trends in real time and quickly identify problems. Because each sample, plate, and well is 
tracked through each of the pipelines, and quality control tests are performed at key steps, 
problems that occur can be rapidly isolated and the cause identified, tested, and resolved. These 
reports are monitored daily by the GRC Directors and provide data about sequencing success, 
read length, and sequence quality by sequencer instrument, sequencing run, project, library, 
operator, and date. When the GRC detects a potential problem in one of the sequencing 
pipelines, these reports are used to identify potential causes.  
 
Consistency is essential to the efficient operation of a high-throughput genomics laboratory. To 
ensure this consistency, all activities within the GRC are based on tested and approved Standard 
Operating Procedures. These SOPs are written in a standardized format and include detailed 
instructions for the performance of each laboratory or bioinformatics protocol. New or modified 
SOPs undergo review and scientific approval by the assigned reviewer and are approved for 
publication to the IGS internal web site and use by the GRC Directors. At minimum, each SOP is 
reviewed annually by the GRC Scientific Director. 
 
Data quality control:  
Clinical data: All clinical information is collected on teleforms that are scanned and the clinical 
information directly loaded to a custom-designed database. The data is doubled checked by 
manual examination by the study coordinator. 
 
Sequence data: 454 pyrosequencing of barcoded 16S rRNA genes: The V1-V2 regions of 16S 
rRNA genes are being sequenced using Roche/454 FLX and Titanium chemistries. To pass 
quality control a sequence read must (a) include a perfect match to the sequence tag (barcode) 
and the 16S rRNA gene primer; (b) be at least 300 bp in length; (c) have no more than two 
undetermined bases; and (d) have at least 60% match to a previously determined 16S rRNA gene 
sequence after alignment with NAST. An average 2,000-4,000 reads are generated per sample. 
The depth of coverage for each community is sufficient to detect taxa that constituted ~0.1% of 
the community. 
 
 
III. DATA ANALYSIS AND PUBLICATION PLANS:   
 
Sequence processing/analysis 
Each processed 16S rRNA gene sequence was classified at a genus level using the RDP Naïve 
Bayesian Classifier. Overall, 70% of all sequence reads generated in this study were 
taxonomically assigned to the genus Lactobacillus. The median RDP Lactobacillus reads score 
was 0.94. About 92% of the reads assigned to the genus Lactobacillus by the RDP classifier had 
a score of 0.8 or higher. 
Species level taxonomic assignment of Lactobacillus 16S rRNA gene sequences  
Because of the short read lengths obtained by 454 pyrosequencing, the classification of 16S 
rRNA sequences using phylogenetic approaches is typically limited to the genus-level. However, 
in studies of vaginal microbiota it is essential to classify Lactobacillus at the species level to 
differentiate the four species of Lactobacillus sp. that distinguish kinds of vaginal communities, 
namely L. crispatus, L. iners, L. jensenii and L. gasserii.  
We used a validated custom algorithm (speciateIT, freely available at speciateit.sourceforge.net) 
to achieve accurate and rapid species level assignments from short V2 16S rRNA genes 
sequences generated by 454 pyrosequencing. This algorithm integrates validated hidden Markov 
models (HMM) for each of the 42 known species of the genus Lactobacillus. The sequence reads 
not assigned to any HMM model were classified as OTUs within the genus Lactobacillus using 
the DBSCAN clustering algorithm on a three-dimensional projection of unclassified reads using 
HMM scores.  
Validation of the HMM based species assignments for Lactobacillus sp. 
To validate the HMM-based speciation algorithm we used the dataset of Zhou et al. (ISME J 
(2007) 1:121-33) who sequenced the 8-926 region of 1,892 cloned 16S rRNA genes of 
Lactobacillus sp. from the vagina and assigned them to species of Lactobacillus using 
phylogenetic algorithms. A total of 6 species of Lactobacillus were identified. The algorithm 
developed for the present study was able to correctly classify each species with 98.69-100% 
accuracy.  
 
Under Aim 3 of the study, we will apply model-based statistical clustering and classification 
approaches to correlate/associate microbial community composition, functions, metadata, and 
BV prognostic. Model-based approaches will be used to analyze the data to define baselines of 
“normal” vaginal microbial community structure and function in individual women, and to 
assess whether deviations from these as well as habits and practices are predictive of BV.  
Statistical analyses 
Most studies done to characterize and classify microbial communities have relied on classical 
statistical tools for grouping and classification such as cluster analysis, principle components 
analysis, correspondence analysis, and multidimensional scaling, among others. These data 
analysis methods are dominated by distance-based approaches that have several limitations. 
First, distance-based methods require reducing the dimensionality of the data in making 
inferences, which results in loss of information. Second, they depend heavily on the type of 
distance measures used and the manner in which results are graphically represented. Third, these 
methods do not provide measures of confidence in the results obtained and it is not possible to 
objectively compare their performance. Finally, there is no straightforward way to incorporate 
metadata associated with the samples analyzed, and this is essential for uncovering important 
correlates between clinical findings and differences in community species/gene composition and 
diversity.  
Model-based approaches are alternatives that overcome the limitations of distance-based 
methods outlined above. Model-based approaches directly use the observed raw data, and 
minimize the loss of information by eliminating the data reduction steps associated with 
distance-based methods. In the original application we proposed to use Bayesian and likelihood 
statistical frameworks and model-based approaches to provide a probabilistic measure of 
confidence in the conclusions. This is done by comparison of different models and methods 
through the use of model-selection strategies such as Bayes factors, Akaike’s information 
criterion, Bayesian information criterion and decision theory. Model-based approaches also 
provide a means for the integrated analysis of metadata and data to classify microbial 
communities and community members. Importantly, these model-based approaches provide a 
classification tool to assign newly sampled individuals to pre-existing, well-established groups 
that result from clustering approaches that take both metadata and microbial community 
composition into account. This provides a framework that is both diagnostic and predictive in 
terms of the ability to identify microbial communities that are prone to BV.  
Ecological Modeling 
The data will also be analyzed using a novel approach that integrates network-analysis and game 
theory to explore microbial community dynamics in the human vagina. The novelty of the 
approach lies in the innovative application of survival analysis and non-equilibrium statistical 
mechanics to build species interaction networks and community metabolomic networks. In 
addition, survival analysis (including multivariate survival analysis) will be used to model 
population abundance, species diversity distributions, lifetimes of “game” players, species 
interactions, and stability modeling. It offers flexibility in modeling time- and covariate-
dependent frailty and the unique capability to handle incomplete information (censoring). We 
contend that these approaches carry advantages over existing ecological modeling approaches 
and constitutes an effective way to create a seamless interface between models used in ecological 
and biomedical research. We believe that our expertise in applying these models will also benefit 
the HMP as a whole, as we continue in providing the groups with bioinformatics analysis tools. 
 
The work will be published rapidly. We anticipate that at least one or two publications describing 
the outcome of these analyses will be generated under this study. 
 
IV. DATA RELEASE PLAN: 
   
NOTE: Due to the nature of the clinical information collected under this study such as sexual 
behaviors, not all the clinical metadata will be released to dbGAP for this project. However, 
researchers could contact the PIs to request access to the entire clinical data.  
 
Sharing of data generated by this project is an essential part of our proposed activities and will be 
carried out in several different ways. We will make the data available to the community of 
researchers and clinicians.  We believe that the proposed work could impact the way scientists 
approach bacterial vaginosis, but also the way clinicians will treat the disease in the future. 
Access to the data generated in this proposal will be critical for these two groups to develop new 
treatment and guidelines for the treatment of bacterial vaginosis. Furthermore, we worked with 
the Data Analysis and Coordination Center (DACC) that support the HMP efforts so that data 
(sequence, metadata and analysis) was available on a timely manner.  
 
Release of clinical data to a controlled access site in NCBI. 
Clinical data has been released to a controlled access site via dbGAP. We are aware of the 
potential sensitivities in making clinical data available and we are willing to participate in any 
discussions related to this topic to ensure that we strike the appropriate balance between 
respecting patient confidentiality and making any relevant clinical data that will aid in 
interpretation of metagenomic datasets available to the investigators who need access to this 
information. We have complied with HMP guidelines to ensure that consenting is appropriate 
and allow release of clinical data in a way that it does not compromise participants privacy. 
 
Release of sequence read and trace data.  
We have been deposited 16S rRNA gene sequences in GenBank, using the standard batch upload 
procedure. One common issue with environmental samples of 16S rRNA is that metadata about 
the environment is lost, which can limit reusability of the sequences in further analyses by other 
investigators. We have addressed this issue by including within the “source” feature an 
“isolation_source” descriptor that stores the string “Homo sapiens vaginal sample”, along with a 
coded patient id, health or BV (Nugent score) status and sample collection data in a comma 
delimited format. This will allow automated parsing tools to assign each sequence to the correct 
sample. Deposition in GenBank ensured inclusion of the sequences in the Ribosomal Database 
Project at http://rdp.cme.msu.edu and GreenGenes (http://greengenes.lbl.gov), both of which 
automatically compiles sequences from GenBank on a monthly basis. 
 
 
Flow Files. All sequences and trace files (Flows) generated under this proposal have been 
submitted to the Short Read Archive at NCBI/NLM/NIH. These data will also include 
information quality values for each sequence. 
 
Release of metadata associated with sequence traces or other types of data. Metadata for this 
project has been deposited into dbGAP.  
 
Release of analysis performed by the awardee. It is our intention to use scientific publications as 
the primary means of releasing the analyses that will be performed in the course of these studies. 
 
Presentations at national/international scientific meetings. Given the scope of the project, we 
are making presentations at national and international meetings to disseminate the analyses and 
results obtained in this study. We are representing the project at key national and international 
meetings so that the scientific community is award of the data generated and knows of our open-
access data release plan. 
 
Web-site (http://www.humvdb.org): The web-site is a portal for this project. We are asking 
visitors who are interested in receiving update on data release to sign up, so that E-mails can be 
sent to this community to announce new data releases and how to access the data. 
 
Resources sharing plan 
The study is generating several types of resources, which we are shared with the scientific and 
clinical research communities, those includes: 
 
Software and analytical pipelines. We believe in open-access to software and bioinformatic 
pipeline. IGS has a track record for making all the source code of their software and pipelines 
available under open-access at sourceforge.org. We have already released speciateIT 
(speciateIT.sourceforge.net) and our visualization tool, inVUE (invue.sourceforge.net). 
 
Technologies and protocols. The proposed project will make use of new technologies and 
protocols.  These will be changing greatly over the course of the project, as technology evolved. 
We will first make all our detailed SOP available to the rest of the HMP awardees, and to the rest 
of the scientific and clinical research communities though the project web-site 
(http://www.humvdb.org) and publications. We will update our protocols as needed and make 
them available as soon as validation is completed. 
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